|1.||Yodoi, Junji: 3 articles (06/2003 - 08/2002)|
|2.||Kishimoto, Chiharu: 3 articles (06/2003 - 08/2002)|
|3.||Kihara, Y: 3 articles (07/2001 - 06/2000)|
|4.||Sasayama, S: 3 articles (07/2001 - 06/2000)|
|5.||Morimoto, Shigeto: 2 articles (09/2006 - 10/2005)|
|6.||Okaishi, Kohya: 2 articles (09/2006 - 10/2005)|
|7.||Okuro, Masashi: 2 articles (09/2006 - 10/2005)|
|8.||Murai, Hiroshi: 2 articles (09/2006 - 10/2005)|
|9.||Iwai, Kunimitsu: 2 articles (09/2006 - 10/2005)|
|10.||Kanda, Tsugiyasu: 2 articles (09/2006 - 10/2005)|
06/01/2003 - "This study was carried out to investigate whether temocapril, a novel non-sulfhydryl containing ACE inhibitor, reduces the severity of myocarditis via redox regulation mechanisms involving TRX. "
05/01/2003 - "This study was carried out to investigate whether temocapril, a novel non-sulfhydryl containing ACE inhibitor, reduces the severity of myocarditis via redox regulation mechanisms involving TRX. "
08/01/2002 - "This study was carried out to investigate whether temocapril, a novel non-sulfhydryl-containing ACE inhibitor, reduces the severity of myocarditis via redox regulation mechanisms involving TRX. "
06/01/2003 - "Temocapril ameliorates myocarditis associated with inducing TRX increase in a preconditioning manner, although the mechanism of TRX induction by temocapril remains to be elucidated."
05/01/2003 - "Temocapril ameliorates myocarditis with inducing TRX up-regulation in a preconditioning manner, although the mechanism of TRX up-regulation by temocapril remains to be elucidated."
01/01/2004 - "In humans temocapril has been found to improve insulin resistance partly by increasing adiponectin levels. "
11/01/2000 - "Temocapril and CS-866 lowered systolic blood pressure, improved insulin resistance, and reduced TNF-alpha in both skeletal muscles. "
09/01/2002 - "These results suggest that temocapril would improve insulin resistance and glucose intolerance through increasing glucose uptake, especially in skeletal muscle at least in part through enhancement of the bradykinin-NO system and consequently GLUT4 translocation."
08/01/1998 - "From these results, it is suggested that in EHT 1) temocapril improves insulin resistance, and 2) although temocapril shows no significant influence on the augmentation of pressor systems by hyperinsulinemia, this agent attenuates the sodium-retaining action of hyperinsulinemia, which may be attributable to suppression of insulin-induced sodium reabsorption at the proximal tubules. "
|3.||Hypertension (High Blood Pressure)
05/01/1993 - "These observations suggest that temocapril is beneficial in the treatment of hypertension in patients with severely impaired renal function."
03/01/1994 - "1. This study was carried out to evaluate the effect of temocapril on haemodynamic and humoral responses to exercise in nine patients with mild essential hypertension (WHO stages I and II). "
11/01/2000 - "These results indicate that long-term therapy with temocapril may be superior in reducing UAE than is diuretic therapy in patients with essential hypertension who had no signs of renal impairment."
11/01/2000 - "Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension."
10/01/1999 - "Time course of the effects of temocapril on cardiovascular structure and function in patients with essential hypertension."
|4.||Chronic Kidney Failure (Chronic Renal Failure)
03/01/2001 - "Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure."
10/01/2001 - "To assess the chronic antihypertensive and renal protective effects of the specific angiotensin II receptor antagonist, CS-866, in the remnant kidney model of chronic renal failure, we administered it alone or in combination with temocapril, an angiotensin converting enzyme inhibitor, to 5/6 nephrectomized spontaneously hypertensive rats (SHR) for 8 weeks. "
05/01/2002 - "To assess the renal benefits of combined angiotensin-converting enzyme inhibition and calcium antagonism, we studied the antihypertensive and renoprotective effects of temocapril (TMP) alone or in combination with azelnidipine (AZN) in a spontaneously hypertensive rat (SHR) remnant kidney model of chronic renal failure. "
10/01/2005 - "Conditional logistic regression analysis according to ACE genotypes revealed significant reduction of pneumonia risk by use of temocapril compared with that in nonhypertensive individuals (ie, the reference group) in those with ACE ID + II (OR: 0. "
10/01/2005 - "Data were collected on medication with the ACE inhibitor temocapril and on known risk factors for pneumonia. "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|3.||olmesartan medoxomil (Votum)
|6.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Angiotensin Receptors (Angiotensin II Receptor)
|10.||Calcium Channels (Calcium Channel)